Modra-based hameln rds invests €7m into development and production of medicines
Modra-based hameln rds, which develops and makes strong painkillers and is owned by the Kerstein family of Germany, improved its net profit 57% to €1m and sales 15% to €11.3m last year. It is investing €7m into drug development and production and aims to increase its sales to €25m annually. The investment will increase its payroll from the current 110 by ten. It also makes substances that are made into drugs in plants in Germany and the UK. The Kerstein family sells €60m worth of drugs annually in Germany and the UK. It is not interested in acquiring the Biotika Slovenská Ľupča pharmaceutical plant, due to the high price asked by owners led by Ivan Varga.
